S. Tran, H. T. Huynh, Toan Hoang Ngo, Anh Thi Hoang Nguyen, C. T. Vo, Thang Nguyen, Minh Van Huynh
{"title":"培哚普利联合吲达帕胺对越南原发性高血压患者动态动脉僵硬指数的影响","authors":"S. Tran, H. T. Huynh, Toan Hoang Ngo, Anh Thi Hoang Nguyen, C. T. Vo, Thang Nguyen, Minh Van Huynh","doi":"10.29090/psa.2022.05.22.107","DOIUrl":null,"url":null,"abstract":"Arterial stiffness is an independent prognostic factor for predicting adverse cardiovascular outcomes in hypertensive patients. This study aimed to investigate the rate of increase in arterial stiffness index and the relationship between the ambulatory arterial stiffness index (AASI) with some cardiovascular risks and the change of AASI after 3 months of treatment with perindopril/indapamide (PER/IND). We conducted this research on 75 untreated hypertensive patients at Can Tho University of medicine and pharmacy, Viet Nam. AASI and pulse pressure (PP) were calculated from 24-hour ambulatory blood pressure results. Our study showed that the mean AASI is 0.44±0.14. Female’s increased AASI is capable of 4.38 times as much as the male. Left ventricular hypertrophy (LVH) can increase arterial stiffness index about 3.93 times as much as the non-hypertrophy group ( p <0.05). AASI is positively correlated with mean pulse pressure and age with r=0.37 and r=0.3 ( p <0.05). After 3 months of treatment, results analysis of the subgroup revealed that AASI decreased 0.06±0.15 in women ( p <0.05). AASI reduced significantly in the group of people aged 65 or more with a mean change to 0.11±0.12 ( p <0.05). Moreover, the group of patients with grade 2 hypertension also indicated that AASI reduced 0.05±0.14 in post-treatment. In conclusion, AASI has been associated with several cardiovascular risk factors such as female, age, nocturnal non-dipper blood pressure, left ventricular hypertrophy, and increased mean pulse pressure. PER/IND has effectively reduced arterial stiffness in Vietnamese patients with primary hypertension, especially women, the elderly, and grade 2 hypertension.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Effectiveness of combination of perindopril and indapamide on ambulatory arterial stiffness index in Vietnamese patients with primary hypertension\",\"authors\":\"S. Tran, H. T. Huynh, Toan Hoang Ngo, Anh Thi Hoang Nguyen, C. T. Vo, Thang Nguyen, Minh Van Huynh\",\"doi\":\"10.29090/psa.2022.05.22.107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Arterial stiffness is an independent prognostic factor for predicting adverse cardiovascular outcomes in hypertensive patients. This study aimed to investigate the rate of increase in arterial stiffness index and the relationship between the ambulatory arterial stiffness index (AASI) with some cardiovascular risks and the change of AASI after 3 months of treatment with perindopril/indapamide (PER/IND). We conducted this research on 75 untreated hypertensive patients at Can Tho University of medicine and pharmacy, Viet Nam. AASI and pulse pressure (PP) were calculated from 24-hour ambulatory blood pressure results. Our study showed that the mean AASI is 0.44±0.14. Female’s increased AASI is capable of 4.38 times as much as the male. Left ventricular hypertrophy (LVH) can increase arterial stiffness index about 3.93 times as much as the non-hypertrophy group ( p <0.05). AASI is positively correlated with mean pulse pressure and age with r=0.37 and r=0.3 ( p <0.05). After 3 months of treatment, results analysis of the subgroup revealed that AASI decreased 0.06±0.15 in women ( p <0.05). AASI reduced significantly in the group of people aged 65 or more with a mean change to 0.11±0.12 ( p <0.05). Moreover, the group of patients with grade 2 hypertension also indicated that AASI reduced 0.05±0.14 in post-treatment. In conclusion, AASI has been associated with several cardiovascular risk factors such as female, age, nocturnal non-dipper blood pressure, left ventricular hypertrophy, and increased mean pulse pressure. PER/IND has effectively reduced arterial stiffness in Vietnamese patients with primary hypertension, especially women, the elderly, and grade 2 hypertension.\",\"PeriodicalId\":19761,\"journal\":{\"name\":\"Pharmaceutical Sciences Asia\",\"volume\":\"35 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical Sciences Asia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29090/psa.2022.05.22.107\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Sciences Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29090/psa.2022.05.22.107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Effectiveness of combination of perindopril and indapamide on ambulatory arterial stiffness index in Vietnamese patients with primary hypertension
Arterial stiffness is an independent prognostic factor for predicting adverse cardiovascular outcomes in hypertensive patients. This study aimed to investigate the rate of increase in arterial stiffness index and the relationship between the ambulatory arterial stiffness index (AASI) with some cardiovascular risks and the change of AASI after 3 months of treatment with perindopril/indapamide (PER/IND). We conducted this research on 75 untreated hypertensive patients at Can Tho University of medicine and pharmacy, Viet Nam. AASI and pulse pressure (PP) were calculated from 24-hour ambulatory blood pressure results. Our study showed that the mean AASI is 0.44±0.14. Female’s increased AASI is capable of 4.38 times as much as the male. Left ventricular hypertrophy (LVH) can increase arterial stiffness index about 3.93 times as much as the non-hypertrophy group ( p <0.05). AASI is positively correlated with mean pulse pressure and age with r=0.37 and r=0.3 ( p <0.05). After 3 months of treatment, results analysis of the subgroup revealed that AASI decreased 0.06±0.15 in women ( p <0.05). AASI reduced significantly in the group of people aged 65 or more with a mean change to 0.11±0.12 ( p <0.05). Moreover, the group of patients with grade 2 hypertension also indicated that AASI reduced 0.05±0.14 in post-treatment. In conclusion, AASI has been associated with several cardiovascular risk factors such as female, age, nocturnal non-dipper blood pressure, left ventricular hypertrophy, and increased mean pulse pressure. PER/IND has effectively reduced arterial stiffness in Vietnamese patients with primary hypertension, especially women, the elderly, and grade 2 hypertension.
Pharmaceutical Sciences AsiaPharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
0.90
自引率
0.00%
发文量
59
期刊介绍:
The Pharmaceutical Sciences Asia (PSA) journal is a double-blinded peer-reviewed journal in English published quarterly, by the Faculty of Pharmacy, Mahidol University, Thailand. The PSA journal is formerly known as Mahidol University Journal of Pharmaceutical Sciences and committed to the timely publication of innovative articles and reviews. This journal is available in both printed and electronic formats. The PSA journal aims at establishing a publishing house that is open to all. It aims to disseminate knowledge; provide a learned reference in the field; and establish channels of communication between academic and research expert, policy makers and executives in industry and investment institutions. The journal publishes research articles, review articles, and scientific commentaries on all aspects of the pharmaceutical sciences and multidisciplinary field in health professions and medicine. More specifically, the journal publishes research on all areas of pharmaceutical sciences and related disciplines: Clinical Pharmacy Drug Synthesis and Discovery Targeted-Drug Delivery Pharmaceutics Biopharmaceutical Sciences Phytopharmaceutical Sciences Pharmacology and Toxicology Pharmaceutical Chemistry Nutraceuticals and Functional Foods Natural Products Social, Economic, and Administrative Pharmacy Clinical Drug Evaluation and Drug Policy Making Antimicrobials, Resistance and Infection Control Pharmacokinetics and Pharmacodynamics.